ReviewThe Journal of molecular diagnostics : JMD2016
Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults.
Review in The Journal of molecular diagnostics : JMD, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 50 citations in OpenAlex.
- Glioma-neuron interactions: insights from neural plasticity.Frontiers in oncology · 2025Review
- Recent updates in pediatric diffuse glioma classification: insights and conclusions from the WHO 5Journal of medicine and life · 2024Review
- Astrocytoma with high-grade features and MYBL1-MMP16 fusion.Surgical neurology international · 2024Article
- Machine learning for cryosection pathology predicts the 2021 WHO classification of glioma.Med (New York, N.Y.) · 2023Article
- Detection of IDH1 Mutation in cfDNA and Tissue of Adult Diffuse Glioma with Allele-Specific qPCR.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Classification and Diagnosis of Adult Glioma: A Scoping Review.Brain & NeuroRehabilitation · 2022Article
- Integrated Transcriptome Profiling Identifies Prognostic Hub Genes as Therapeutic Targets of Glioblastoma: Evidenced by Bioinformatics Analysis.ACS omega · 2022Article
- Molecular alterations of low-grade gliomas in young patients: Strategies and platforms for routine evaluation.Neuro-oncology practice · 2021Review
- Concise review of stereotactic irradiation for pediatric glial neoplasms: Current concepts and future directions.World journal of methodology · 2021Review
- Establishment of an Endocytosis-Related Prognostic Signature for Patients With Low-Grade Glioma.Frontiers in genetics · 2021Article
- Demethoxycurcumin analogue DMC-BH exhibits potent anticancer effects on orthotopic glioblastomas.Aging · 2020Article
- Non-coding RNAs in Brain Tumors, the Contribution of lncRNAs, circRNAs, and snoRNAs to Cancer Development-Their Diagnostic and Therapeutic Potential.International journal of molecular sciences · 2020Review
- Role of molecular biomarkers in glioma resection: a systematic review.Chinese neurosurgical journal · 2020Review
- IDH Mutation Analysis in Glioma Patients by CADMA Compared with SNaPshot Assay and two Immunohistochemical Methods.Pathology oncology research : POR · 2019Article
- Trends in Pediatric Central Nervous System Tumor Incidence in the United States, 1998-2013.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019Article
- Article
- Pediatric Glioma at the Optic Pathway and Thalamus.Journal of Korean Neurosurgical Society · 2018Review
- PARP10 (ARTD10) modulates mitochondrial function.PloS one · 2018Article
- Clinical relevance of screening checklists for detecting cancer predisposition syndromes in Asian childhood tumours.NPJ genomic medicine · 2018Article
- Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.Virchows Archiv : an international journal of pathology · 2017Article
Corrections and comments
- Erratum issuedCorrection.2016
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Gliomas represent the most common primary intraparenchymal tumors of the central nervous system in adults and children and are a genetic and phenotypic heterogeneous group. Large multi-institutional studies and The Cancer Genome Atlas have provided firm insights into the basic genetic drivers in gliomas. The main molecular biomarkers routinely applied to evaluate diffuse gliomas include MGMT promoter methylation, EGFR alterations (eg, EGFRvIII), IDH1 or IDH2 mutations, and 1p19q co-deletion. Many of these markers have become standard of care for molecular testing and prerequisites for clinical trial enrollment. Other recent biomarkers include TERT promoter and ATRX mutations, alterations that identify specific molecular subgroups of diffuse gliomas with biological and clinical relevance. It has also become apparent that distinctive patterns of molecular genetic evolution develop in the context of current therapeutic regimens. Important insights have also been uncovered in the field of pediatric glioma, including the identification of recurrent mutation, fusion, and/or duplication events of the BRAF, FGFR1, MYB, and MYBL1 genes in pediatric low-grade gliomas, mutations affecting histone components (H3F3A p.K27M or p.G34) in pediatric high-grade gliomas, and aggressive subsets developing in midline central nervous system structures. Here, we summarize current concepts in molecular testing for glial tumors, including recent findings by large-scale discovery efforts and technologic advances that are affecting routine diagnostic work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.